United Immunity, Co., Ltd. is an innovative biotech company with drug candidates for refractory cancer and other cancers using our proprietary nanoparticle drug delivery technology (Myeloid Targeting PlatformTM), which is selective for macrophages and dendritic cells.
A patent application (PCT/JP2022/030928; JP2023-534246 “Cancer Therapeutic Agent”) protecting the relationship between our nanoparticles and its target receptor DC-SIGN has recently been granted a patent in Japan. We will continue to protect our platform technology on a global basis, with the aim of obtaining patent rights in the US, Europe and other countries as soon as possible.

＜Concept of Myeloid Targeting Platform^TM＞